Youjin Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Youjin Kim has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Cheolkyung Sin
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea
2 shared publications - Hyeon-Su Im
Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, Republic of Korea
2 shared publications - Hyeyeong Kim
Department of Hematology and Oncology, University of Ulsan College of Medicine, Ulsan, Republic of Korea
2 shared publications - Jae-Cheol Jo
Department of Hematology and Oncology, Ulsan University Hospital University of Ulsan College of Medicine Ulsan Republic of Korea
2 shared publications - Su-Jin Koh
Department of Hematology and Oncology, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
2 shared publications - Yoo Jin Lee
Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by The Korean Society of Clinical Neurophysiology in Annals of Clinical Neurophysiology
- Vol. 28 (2) , 67-76
Clinical, electrophysiological, cutaneous sensory, and autonomic changes in patients with multiple myeloma following bortezomib treatment
Background: Bortezomib-induced peripheral neuropathy (BIPN) is a significant adverse effect following bortezomib administration for multiple myeloma (MM). The clinical presentation of BIPN, its predictive factors, and the role of pre-existing neuropathy remain unclear. This study aimed to provide comprehensive clinical and electrophysiological profiles of BIPN, its baseline predictors, and the role of pre-existing neuropathy.Methods: This prospective longitudinal observational study involved 27 patients with newly diagnosed MM. Their neurological features were assessed before and after four cycles of bortezomib-based chemotherapy using four validated outcome measures and three types of electrophysiological testing: the reduced Total Neuropathy Score (TNS-r), Composite Autonomic Symptom Score-31, Small Fiber Neuropathy Symptom Inventory Questionnaire, Korean Neuropathic Pain Questionnaire, nerve conduction studies, quantitative sensory testing, and quantitative sudomotor axon reflex testing (QSART).Results: Bortezomib treatment significantly worsened the TNS-r (p = 0.0033), primarily due to sensory symptoms and signs, with cold pain being the most-affected sensory symptom. Significant deterioration was also observed in the sensory nerve action potential (SNAP) amplitude, cold detection threshold, and QSART score. Baseline predictors of clinically evident BIPN (TNS-r ≥3) were the ulnar compound muscle action potential amplitude, median SNAP amplitude, and QSART score. Some patients with baseline neuropathic pain or autonomic dysfunction experienced considerable improvement following treatment.Conclusions: BIPN primarily causes sensory symptoms and axonal degeneration, and may be predicted by several baseline electrophysiological parameters. The unexpected improvement in pre-existing neuropathic pain and autonomic symptoms during chemotherapy in some patients warrants further clinical and mechanistic investigations.
- 31 October 2026
- Published by The Korean Society of Clinical Neurophysiology in Annals of Clinical Neurophysiology
- Vol. 28 (2) , 67-76
Open AccessClinical, electrophysiological, cutaneous sensory, and autonomic changes in patients with multiple myeloma following bortezomib treatment
Background: Bortezomib-induced peripheral neuropathy (BIPN) is a significant adverse effect following bortezomib administration for multiple myeloma (MM). The clinical presentation of BIPN, its predictive factors, and the role of pre-existing neuropathy remain unclear. This study aimed to provide comprehensive clinical and electrophysiological profiles of BIPN, its baseline predictors, and the role of pre-existing neuropathy.Methods: This prospective longitudinal observational study involved 27 patients with newly diagnosed MM. Their neurological features were assessed before and after four cycles of bortezomib-based chemotherapy using four validated outcome measures and three types of electrophysiological testing: the reduced Total Neuropathy Score (TNS-r), Composite Autonomic Symptom Score-31, Small Fiber Neuropathy Symptom Inventory Questionnaire, Korean Neuropathic Pain Questionnaire, nerve conduction studies, quantitative sensory testing, and quantitative sudomotor axon reflex testing (QSART).Results: Bortezomib treatment significantly worsened the TNS-r (p = 0.0033), primarily due to sensory symptoms and signs, with cold pain being the most-affected sensory symptom. Significant deterioration was also observed in the sensory nerve action potential (SNAP) amplitude, cold detection threshold, and QSART score. Baseline predictors of clinically evident BIPN (TNS-r ≥3) were the ulnar compound muscle action potential amplitude, median SNAP amplitude, and QSART score. Some patients with baseline neuropathic pain or autonomic dysfunction experienced considerable improvement following treatment.Conclusions: BIPN primarily causes sensory symptoms and axonal degeneration, and may be predicted by several baseline electrophysiological parameters. The unexpected improvement in pre-existing neuropathic pain and autonomic symptoms during chemotherapy in some patients warrants further clinical and mechanistic investigations.
- Open Access
- 8 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26
Impact of unmet needs on health-related quality of life among cancer survivors in Ulsan, Korea
Cancer survivorship care emphasizes biomedical interventions, but psychological and social difficulties remain underaddressed. This study aimed to (i) quantify the association between unmet needs and quality of life (QOL), and (ii) evaluate whether these associations are consistent across two health-related QOL (HRQoL) instruments among cancer survivors. Cross-sectional survey of adults (≥ 19) in Ulsan, Korea (2021, 2022). HRQoL (EQ-5D-5 L; EORTC QLQ-C30) was related to unmet-need domains using multivariable linear regression adjusted for prespecified sociodemographic and clinical covariates (gender, age, cancer type/stage, education level, household size, household monthly income, smoking status, alcohol consumption). Statistical analyses included Student's t-tests, one-way ANOVA, and multivariable linear regression. After excluding cases with insufficient information, 372 survivors were analyzed. EQ-5D-5 L utility was negatively associated with age ≥ 60 years (B=-0.04, 95%CI[-0.07, -0.01]), advanced cancer stage (Stage IV: B=-0.11, 95%CI[-0.14, -0.07]), unmet psychological needs (B=-0.09, 95%CI[-0.13, -0.06]), and unmet financial needs (B=-0.04, 95%CI[-0.09, -0.001]). On the EORTC QLQ-C30, advanced cancer stage showed negative associations with the functional scale (Stage IV: B=-14.87, 95%CI[-18.65, -11.10]) and positive associations with the symptom scale (Stage IV: B = 9.01, 95%CI[6.44, 11.57]). Higher household income (B = 4.99, 95%CI[1.71, 8.26]) was positively associated with the functional scale, while unmet psychological needs were negatively associated with the functional scale (B=-5.96, 95%CI[-10.04, -1.89]) and positively associated with the symptom scale (B = 8.80, 95%CI[6.04, 11.57]). Unmet psychological needs showed the most consistent associations with poorer HRQoL across both generic and cancer-specific instruments. Unmet financial needs showed weaker but directionally consistent associations, and the concurrent use of both instruments provided complementary perspectives on survivorship-related quality of life.
- 8 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26
Open AccessImpact of unmet needs on health-related quality of life among cancer survivors in Ulsan, Korea
Cancer survivorship care emphasizes biomedical interventions, but psychological and social difficulties remain underaddressed. This study aimed to (i) quantify the association between unmet needs and quality of life (QOL), and (ii) evaluate whether these associations are consistent across two health-related QOL (HRQoL) instruments among cancer survivors. Cross-sectional survey of adults (≥ 19) in Ulsan, Korea (2021, 2022). HRQoL (EQ-5D-5 L; EORTC QLQ-C30) was related to unmet-need domains using multivariable linear regression adjusted for prespecified sociodemographic and clinical covariates (gender, age, cancer type/stage, education level, household size, household monthly income, smoking status, alcohol consumption). Statistical analyses included Student's t-tests, one-way ANOVA, and multivariable linear regression. After excluding cases with insufficient information, 372 survivors were analyzed. EQ-5D-5 L utility was negatively associated with age ≥ 60 years (B=-0.04, 95%CI[-0.07, -0.01]), advanced cancer stage (Stage IV: B=-0.11, 95%CI[-0.14, -0.07]), unmet psychological needs (B=-0.09, 95%CI[-0.13, -0.06]), and unmet financial needs (B=-0.04, 95%CI[-0.09, -0.001]). On the EORTC QLQ-C30, advanced cancer stage showed negative associations with the functional scale (Stage IV: B=-14.87, 95%CI[-18.65, -11.10]) and positive associations with the symptom scale (Stage IV: B = 9.01, 95%CI[6.44, 11.57]). Higher household income (B = 4.99, 95%CI[1.71, 8.26]) was positively associated with the functional scale, while unmet psychological needs were negatively associated with the functional scale (B=-5.96, 95%CI[-10.04, -1.89]) and positively associated with the symptom scale (B = 8.80, 95%CI[6.04, 11.57]). Unmet psychological needs showed the most consistent associations with poorer HRQoL across both generic and cancer-specific instruments. Unmet financial needs showed weaker but directionally consistent associations, and the concurrent use of both instruments provided complementary perspectives on survivorship-related quality of life.
- Open Access
- 15 October 2024
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 56 (4) , 1068-1076
Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials
Purpose In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).Materials and Methods We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed.Results In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6%, 12.4%, and 18.1% months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor.Conclusion Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.
- 15 October 2024
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 56 (4) , 1068-1076
Open AccessAnalysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials
Purpose In this study, we evaluated 66 patients diagnosed with adenoid cystic carcinoma (ACC) enrolled in two Korean Cancer Study Group trials to investigate the response and progression patterns in recurrent and/or metastatic ACC treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs).Materials and Methods We evaluated 66 patients diagnosed with ACC who were enrolled in the Korean Cancer Study Group trials. The tumor measurements, clinical data, treatment outcomes, and progression patterns of therapy were analyzed.Results In the 66 patients (53 receiving axitinib and 13 receiving nintedanib), the disease control rate was 61%, and three patients achieved partial response. The median follow-up, median progression-free survival (PFS), overall survival, and 6-month PFS rate were 27.6%, 12.4%, and 18.1% months and 62.1%, respectively. Among 42 patients who experienced progression, 27 (64.3%) showed target lesion progression. Bone metastasis was an independent poor prognostic factor.Conclusion Overall, most patients demonstrated stable disease with prolonged PFS; however, prominent target lesion progression occurred in some patients. Thus, PFS may capture VEGFR-TKI efficacy better than the objective response rate.
- Open Access
- 25 December 2023
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 20 (12) , 1204-1210
Catastrophizing Maladaptive Coping Affects the Association Between Viral Anxiety and Fear of Progression in Cancer Patients During COVID-19 Pandemic
Objective The aim of the present study was to explore whether or not cancer patients’ viral anxiety and depression during the coronavirus-2019 (COVID-19) pandemic were associated with a fear of cancer progression. We also assessed whether coping strategies affected the relationship.Methods The present cross-sectional survey included cancer patients who visited Ulsan University Hospital in Ulsan, Korea. The participants’ demographic information and responses to the following symptoms rating scales were collected: Stress and Anxiety to Viral Epidemic–6; Patient Health Questionnaire–9; Cognitive Emotion Regulation Questionnaire-short version; or Fear of Progression Questionnaire-short version.Results Of the 558 cancer patients surveyed, 25 (4.5%) reported that their treatment schedule was delayed during the COVID-19 pandemic. The patients’ fear of progression was found to be related to age (β=-0.08; p=0.011), viral anxiety (β=0.40; p<0.001), depression (β=0.26; p<0.001), and catastrophizing coping strategies (β=0.15; p=0.004), for an overall adjusted R2 of 0.46 (F=66.8; p<0.001). Mediation analysis showed that viral anxiety and depression were directly associated with fear of progression, while catastrophizing mediated this relationship.Conclusion Fear of progression in cancer patients was associated with viral anxiety, depression, and maladaptive coping techniques, such as catastrophizing, during the COVID-19 pandemic.
- 25 December 2023
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 20 (12) , 1204-1210
Open AccessCatastrophizing Maladaptive Coping Affects the Association Between Viral Anxiety and Fear of Progression in Cancer Patients During COVID-19 Pandemic
Objective The aim of the present study was to explore whether or not cancer patients’ viral anxiety and depression during the coronavirus-2019 (COVID-19) pandemic were associated with a fear of cancer progression. We also assessed whether coping strategies affected the relationship.Methods The present cross-sectional survey included cancer patients who visited Ulsan University Hospital in Ulsan, Korea. The participants’ demographic information and responses to the following symptoms rating scales were collected: Stress and Anxiety to Viral Epidemic–6; Patient Health Questionnaire–9; Cognitive Emotion Regulation Questionnaire-short version; or Fear of Progression Questionnaire-short version.Results Of the 558 cancer patients surveyed, 25 (4.5%) reported that their treatment schedule was delayed during the COVID-19 pandemic. The patients’ fear of progression was found to be related to age (β=-0.08; p=0.011), viral anxiety (β=0.40; p<0.001), depression (β=0.26; p<0.001), and catastrophizing coping strategies (β=0.15; p=0.004), for an overall adjusted R2 of 0.46 (F=66.8; p<0.001). Mediation analysis showed that viral anxiety and depression were directly associated with fear of progression, while catastrophizing mediated this relationship.Conclusion Fear of progression in cancer patients was associated with viral anxiety, depression, and maladaptive coping techniques, such as catastrophizing, during the COVID-19 pandemic.